雌激素受体轴向治疗和前列腺癌中的抗血栓治疗之间的药物相互作用:德尔菲共识
Kori Leblanc1,2, Scott J Edwards3,4, George Dranitsaris5
1Department of Pharmacy, University Health Network, Toronto, ON M5G 2C4, Canada.
Cancers
|October 16, 2024
概括
专家建议避免11种雄激素受体轴向治疗 (ARAT) 和抗血栓药物组合,并对另外8种药物进行修改治疗,因为它们可能在前列腺癌患者中产生相互作用.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
背景情况:
- 针对雄激素受体轴的疗法 (ARAT),如阿比拉酸,阿帕胺,达罗胺和恩扎胺,在前列腺癌的治疗中至关重要.
- 与口服抗血栓治疗 (抗凝血剂/抗血小板药物) 同时使用ARAT是常见的,这引发了对药物相互作用 (DDI) 的担忧.
- 关于这些特定的ARAT抗血栓DDI的临床后果和管理指南的文献有限.
研究的目的:
- 建立专家的共识,在ARATs和抗血栓治疗之间临床显著的药物相互作用.
- 为在接受两类药物治疗的前列腺癌患者中管理潜在的DDI提供指导.
主要方法:
- 一个三步修改的电子Delphi过程,涉及一个多学科专家小组.
- 综合性文献审查,以告知关于ARAT/抗血栓DDI的小组讨论.
- 通过对药物配对,临床后果和管理策略进行多轮投票,建立共识.
主要成果:
- 达成共识,避免使用11种特定的ARAT/抗血栓治疗药物对.
- 达成共识,修改八种ARAT/抗血栓治疗药物对的治疗.
- 评估主要利用药理动力学数据和类似药物代谢研究的推断.
结论:
- 在e-Delphi过程中,确定了需要临床关注的关键ARAT/抗血栓药物相互作用.
- 该研究强调需要进一步研究这些DDI的临床影响.
- 建议的管理行动为临床医生管理前列腺癌患者的这些并发疗法提供了实际框架.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
480
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
480
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
155
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
155
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:29Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137